Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 8/20 | 0.53 |
| ▸ | APP | P05067 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | SNCA | P37840 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9305718 | 0.83 | SMN1; SMN2 (0.53) | RAB9AMAPTNPC1APPKDM4E | |
| SCHEMBL13444809 | 0.81 | MAPT (0.69) | RAB9AMAPTNPC1APPKDM4E | |
| SCHEMBL84327 | 0.81 | SMN1; SMN2 (0.66) | RAB9AMAPTNPC1APPKDM4E | |
| SCHEMBL30542465 | 0.81 | SMN1; SMN2 (0.66) | RAB9AMAPTNPC1APPKDM4E | |
| SCHEMBL7601340 | 0.79 | RAB9A (0.67) | RAB9AMAPTNPC1APPKDM4E | |
| SCHEMBL2098849 | 0.78 | RAB9A (0.56) | RAB9AMAPTNPC1APPDYRK1A | |
| SCHEMBL25165513 | 0.78 | RAB9A (0.61) | RAB9AMAPTNPC1APPKDM4E | |
| SCHEMBL2231243 | 0.78 | RAB9A (0.61) | RAB9AMAPTNPC1APPKDM4E | |
| SCHEMBL10435968 | 0.78 | RAB9A (0.61) | RAB9AMAPTNPC1APPKDM4E | |
| SCHEMBL780451 | 0.78 | RAB9A (0.61) | RAB9AMAPTNPC1APPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | claimed |
| CN-1980922-A | New compounds useful for treating CNS disorders | ASTRAZENECA AB (SE) | 2007-06-13 | — | — | CN | claimed |
| EP-1765815-A2 | NEW COMPOUNDS USEFUL FOR TREATING CNS DISORDERS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | claimed |
| WO-2006004507-A2 | NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | claimed |
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | CHECKMATE THERAPEUTICS INC. (KR) | 2026-01-22 | — | — | US | disclosed |
| WO-2023229346-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | 주식회사 체크메이트테라퓨틱스 | 2023-11-30 | — | — | WO | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-9708353-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-07-18 | — | — | US | disclosed |
| CN-106905311-A | Adjust the compound of intracellular Ca2+ | 钙医学公司 | 2017-06-30 | — | — | CN | disclosed |
| CN-103601698-B | Benzothiazole compound and application thereof | 沈阳药科大学 | 2016-08-17 | — | — | CN | disclosed |
| CN-101918380-B | Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and cns disorders | DECODE GENETICS EHF | 2014-09-24 | — | — | CN | disclosed |
| EP-2766359-A2 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES | Ambit Biosciences Corporation (US) | 2014-08-20 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| WO-2006004507-A2 | NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
| CN-1699363-A | Vla-4 inhibitors | DAICHI PHARMACEUTICAL CO LTD (JP) | 2005-11-23 | — | — | CN | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| CN-1483024-A | Vla-4 inhibitors | ��һ��������ҩ��ʽ���� | 2004-03-17 | — | — | CN | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | RAB9A 2530/4885MAPT 4631/4885NPC1 1278/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | RAB9A 2849/4885MAPT 741/4885NPC1 2637/4885 |
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | SLC18A2, PMP22, GAP43 | RAB9A 726/4885MAPT 96/4885NPC1 84/4885 |
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | NAMPT, NAPRT, NNT | RAB9A 1585/4885MAPT 1402/4885NPC1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.